Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Resveratrol and Vascular Function

Huige Li, Ning Xia, Solveig Hasselwander and 1 more (opens in a new tab)

International Journal of Molecular Sciences · 2019 · Review · CC BY-NC

doi:10.3390/ijms20092155 (opens in a new tab)

Abstract

Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling. At the same time, resveratrol inhibits the synthesis of endothelin-1 and reduces oxidative stress in both endothelial cells and smooth muscle cells. Pathological stimuli-induced smooth muscle cell proliferation, vascular remodeling, and arterial stiffness can be ameliorated by resveratrol as well. In addition, resveratrol also modulates immune cell function, inhibition of immune cell infiltration into the vascular wall, and improves the function of perivascular adipose tissue. All these mechanisms contribute to the protective effects of resveratrol on vascular function and blood pressure in vivo. Sirtuin 1, AMP-activated protein kinase, and estrogen receptors represent the major molecules mediating the vascular effects of resveratrol.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Resveratrol and its Molecular Targets

The polyphenolic phytoalexin 3,5,4′-trihydroxy-trans-stilbene, better known under its trivial name resveratrol, can be found in numerous plants, such as white hellebore (Veratrum grandiflorum), mulberry (Morus rubra), peanut (Archis hypogaea), and grapes (Vitis vinifera).

Since resveratrol gained popularity in 1992, many targets responsible for its pharmacological effects have been identified. These targets can be divided into those which directly interact with resveratrol (over 20) and those whose effects are indirectly changed, e.g., by modulation of their expression level. Regarding vascular function, especially the estrogen receptor (ER), the NAD+-dependent, class III histone deacetylase sirtuin 1 (SIRT1), the nuclear factor-erythroid-derived 2-related factor-2 (Nrf2), and the AMP-activated protein kinase (AMPK) are of particular importance.

Resveratrol can directly activate SIRT1 on certain substrates. Indirectly, resveratrol increases SIRT1 activity either through elevation of intracellular NAD+ concentration, which is dependent on an inhibition of phosphodiesterase (PDE), or through an enhancement of the binding of SIRT1 to lamin A, an endogenous SIRT1 activator. In addition, the SIRT1-dependent effects of resveratrol in vivo are partially attributable to an upregulation of SIRT1 expression by the compound.

Nrf2 is an indirect target protein of resveratrol. For its stimulation, concentrations of resveratrol lower than 1 µM are sufficient (lower than that for SIRT1), making its activation possible by using resveratrol as a dietary supplement. Nrf2 interacts with antioxidant-response elements after its translocation to the nucleus. Here, it triggers the expression of phase II and antioxidant defense enzymes, like heme oxygenase-1 (HO-1).

As mentioned before, resveratrol has been linked to PDE inhibition. One result of this effect is the phosphorylation of AMPK. Another suggested pathway for AMPK activation is based on LKB1 stimulation, e.g., by reduction of the intracellular ATP level or its deacetylation by SIRT1. Interestingly, AMPK and SIRT1 seem to function synergistically and bolster one another.

Resveratrol can directly bind the estrogen receptors (ERs). Very low (nanomolar) concentrations of resveratrol are enough for the ER-mediated stimulation of endothelial NO synthase (eNOS). Additionally, resveratrol-mediated ER-stimulation has also been linked to HO-1 upregulation as well as to Nox downregulation.

Also, the effects of resveratrol in vivo may also involve its actions on potassium channels, gut microbiota, and circadian gene expression.

2. Effects of Resveratrol on Endothelial Cells

The endothelium, consisting of a single layer of flat, longish endothelial cells, covers the inner walls of blood vessels. Vascular endothelial cells are unique in their property of holding Weibel-palade bodies, the depot for the Von Willebrand factor which is crucial for hemostasis maintenance. Apart from its function in maintaining blood coagulation and serving as starting point for angiogenesis, the endothelium also provides a semi-permeable barrier to regulate the transfer of electrolytes, macromolecules, and fluid between the intravascular and the extravascular space. Endothelial cells synthesize important vasoactive substances, including prostacyclin, NO, and the vasocontractile endothelin-1 (ET-1). Therefore, endothelial cells are key regulators of blood pressure and vascular tone.

2.1. Resveratrol Enhances Endothelial NO Production

Under physiological conditions, the endothelial NO synthase (eNOS) is the main producer of vascular NO. It confers antithrombotic, antihypertensive, and anti-atherosclerotic effects. Endothelial NO reaches the smooth muscle cells (SMC) by diffusion and causes vasodilation. In the blood, eNOS-produced NO prevents platelet aggregation and adhesion. The anti-atherosclerotic properties of NO include the prevention of leukocyte adhesion to and migration into the vascular wall as well as the repression of low-density lipoprotein oxidation and the proliferation of vascular smooth muscle cells. Suppression of the eNOS gene in mice leads to blood pressure elevation and atherosclerosis aggravation. Recently, it has been shown that eNOS-produced NO might be involved in mitochondrial biogenesis boosting and could be partly responsible for the observed antiaging effects in calorie restriction studies. In addition, it has been demonstrated that eNOS-knockout mice exhibit insulin resistance as well as hyperinsulinemia, while overexpression of eNOS protects mice fed with a high-fat diet (HFD) from pathological weight gain.

Resveratrol increases endothelial NO production through multiple mechanisms (Figure 1), including upregulation of eNOS expression, enhancement of eNOS enzymatic activity, and prevention of eNOS uncoupling.

2.1.1. Resveratrol Upregulates eNOS Expression

Resveratrol increases eNOS expression in endothelial cells. eNOS is constitutively expressed in the endothelium; its expression level changes in response to various stimuli and compounds. We have previously shown that resveratrol itself as well as resveratrol-containing red wines enhance eNOS expression in endothelial cells (Table 1). Interestingly, this phenomenon is not dependent on ERs but associates with transcriptional and posttranscriptional mechanisms. In endothelial cells, knock-down of the SIRT1 gene via siRNA inhibits the up-regulation of eNOS by resveratrol treatment. Correspondingly, an endothelium-specific overexpression of SIRT1 leads to elevated eNOS expression. Therefore, resveratrol-induced up-regulation of eNOS is likely to be SIRT1-dependent. Strengthening this suggestion, we were recently able to show the involvement of FOXO factors as downstream targets of SIRT1 in resveratrol effects.

2.1.2. Resveratrol Increases eNOS Activity

In addition to eNOS expressional upregulation, resveratrol also enhances enzymatic activity of eNOS through post-translational modifications. Phosphorylation of eNOS at Ser-1177 is an activating modification. Resveratrol has been shown to increase eNOS Ser-1177 phosphorylation in cultured endothelial cells. For this effect, resveratrol concentrations of the nanomolar range are sufficient. The underlying signaling pathway includes the estrogen receptor ERα, G-protein Gα, caveolin-1 (Cav-1), the tyrosine kinase c-Src, and the MAP kinase Erk1/2. In concentrations of the micromolar range, phosphorylation of eNOS at the Ser-1177 by resveratrol also involves the activation of the AMPK. Additionally, resveratrol enhances eNOS activity by inducing SIRT1-mediated deacetylation of eNOS at Lys-496 and Lys-506.

An established endogenous eNOS inhibitor is asymmetric dimethylarginine (ADMA). Its degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH) was found to be down-regulated by high concentrations of glucose, resulting in intracellular ADMA accumulation. This development, however, can be prevented by pre-treating of the cells with resveratrol.

Another negative regulator of eNOS is Cav-1. It was shown in vitro (endothelial cells) and in vivo (rat heart) that resveratrol targets these protein–protein interactions both by reduction of the Cav-1 expression level and by restriction of the Cav-1/eNOS association.

2.1.3. Resveratrol Prevents eNOS Uncoupling

Importantly, resveratrol also prevents eNOS uncoupling. This terminology describes the phenomenon of superoxide production by eNOS under pathological conditions. Major mechanisms underlying eNOS uncoupling are the lack of the eNOS substrate l-arginine or the eNOS cofactor BH4 as well as eNOS S-glutathionylation. Causes for BH4 insufficiency are its oxidation by potent oxidizing agents, such as peroxynitrite and superoxide. This event and the following eNOS uncoupling though, can be prevented by resveratrol due to its antioxidant effects. Additionally, resveratrol boosts BH4 biosynthesis by enhancing the expression of GTP cyclohydrolase 1, an essential enzyme for BH4 production. We previously described the vicious circle resulting from eNOS uncoupling leading to a potentiation of oxidative stress as a central mechanism adding to cardiovascular diseases. Resveratrol intervenes in this circle by avoiding eNOS uncoupling and excess oxidative stress (Table 2).

2.2. Resveratrol Reduces Endothelial Oxidative Stress

Since the capacity of resveratrol to directly eliminate free radicals is lower than that of already established antioxidant reagents, the means by which it diminishes oxidative stress in vivo are more likely due to its ability to regulate gene expression (Figure 2). Indeed, resveratrol is a potent gene regulator. At a concentration of 0.1 µM, resveratrol has been shown to upregulate 127 genes and downregulate 233 genes in cultured human umbilical vein endothelial cells (HUVEC).

In cultured endothelial cells, resveratrol enhances the expression of phase 2 enzymes and antioxidant enzymes, including NAD(P)H:quinone–oxidoreductase 1 (NQO1), γ-glutamylcysteine synthetase (GCLC), HO-1, SOD1, SOD2, glutathione peroxidase 1 (GPx1), and catalase. The expression and activity of NADPH oxidases, major ROS-producing enzymes in endothelial cells, are reduced by resveratrol (Table 2). Furthermore, resveratrol improves mitochondrial biogenesis and thus diminishes mitochondrial superoxide production.

SIRT1 and Nrf2 play important roles in the expressional regulation of redox genes by resveratrol. Resveratrol-induced upregulation of SOD1, SOD2, GPx1, and catalase requires SIRT1, whereas Nrf2 is responsible for the upregulation of HO-1, NQO1, and GCLC by resveratrol.

2.3. Resveratrol Reduces Endothelin-1 Synthesis

ET-1 is a highly potent vasoconstrictor. Overproduction of ET-1 is implicated in the development of vascular disease and atherosclerosis. Interestingly, resveratrol has been shown to reduces ET-1 synthesis in endothelial cells and smooth muscle cells (Table 3), as well as in the plasma of resveratrol-treated rabbits. It is conceivable that both the enhanced production of NO and reduced synthesis of ET-1 are involved in the vasodilation and blood pressure reduction by resveratrol in vivo.

3.1. Resveratrol Reduces Oxidative Stress in Smooth Muscle Cells

Resveratrol has been shown to produce biphasic effects on HO-1 expression in human aortic SMC in a NF-κB-dependent manner, with a HO-1 induction at low concentrations of resveratrol (1–10 μM) and a reduction at high concentrations of resveratrol (≥20 μM). This phenomenon has not been observed in later studies. In in rat aortic SMC, resveratrol (1–30 µM) causes a concentration-dependent upregulation of HO-1 mediated by Nrf2.

Treatment of cultured rat aortic SMC with resveratrol (25–100 µM) leads to upregulation of SOD, catalase, glutathione, glutathione reductase, glutathione peroxidase, glutathione S-transferase (GST) and NOQ1. GST and NQO1 are typical phase 2 enzymes responsible for detoxification of both ROS and electrophilic xenobiotics. The induction of such cellular antioxidants and phase 2 enzymes by resveratrol protects the cells from oxidative stress and oxidants-induced cytotoxicity (Table 4).

3.2. Resveratrol Inhibits Smooth Muscle Cell Proliferation

Normally differentiated vascular smooth muscle cells (VSMC) express a specific set of contractile proteins, have low synthetic activity, and proliferate slowly. Upon stimulation by growth factor or in response to vascular injury, VSMC can change their phenotype through de-differentiation, proliferation, and migration to the site of injury. While the phenotypic plasticity in VSMC is essential for the maintenance and repair of the vasculature, excessive proliferation of VSMC promotes the development of atherosclerosis, restenosis, and pulmonary hypertension.

Resveratrol has been shown to inhibit VSMC proliferation induced by various mitogens (Table 4). Depending on the mitogenic stimuli, the molecular mechanisms include inhibition of PI3K/Akt/mTOR pathway or cell cycle arrest (Table 4). In addition, antiproliferative effects in VSMC have also been reported for the resveratrol tetramer vitisin B and for pterostilbene, a natural dimethylated analog of resveratrol

Oral administration of resveratrol has been shown to significantly suppress intimal hyperplasia in mouse models of wire-injured arteries. Intraperitoneal injection of resveratrol also inhibited the development of intimal hyperplasia in the rat carotid artery injury model.

Because of the low bioavailability of systemically administrated resveratrol, local delivery may represent a promising method improving the in vivo efficacy of the compound. Resveratrol coated on a stent reduced stenosis in rat carotid artery by 65%. In a recent study of rat carotid balloon angioplasty, resveratrol was applied in Pluronic gel around the injured artery. Strikingly, periadventitial application of resveratrol significantly improved all three major pathologies contributing to restenosis: VSMC hyperplasia in the intima, impairment of re-endothelialization, and constrictive remodeling. Periadventitial delivery of resveratrol produced a much greater neointima-inhibiting effect (86%) than systemic resveratrol administration reported in previous studies. Moreover, post-surgery endothelial recovery was accelerated by resveratrol without causing constrictive remodeling. These are compelling advantages over drug-eluting stents currently used in clinical settings.

3.3. Resveratrol Prevents Arterial Stiffness and Vascular Remodeling

In addition to inhibition of VSMC proliferation, resveratrol also prevents vascular remodeling and arterial stiffness. In cultured rat aortic SMC stimulated with advanced glycation end-products (AGEs), resveratrol reduces TGF-β1 expression and collagen synthesis. In human VSMC, TNF-α-induced expression of matrix metalloproteinase (MMP)-9 is inhibited by resveratrol.

Resveratrol has been shown to prevent high-fat, high-sucrose diet-induced arterial stiffness in mice. This effect is likely to be mediated by SIRT1, because similar effects can be achieved with SIRT1 activators or by global SIRT1 overexpression. Interestingly, overnight fasting acutely decreased arterial stiffness in wildtype mice but not in mice lacking SIRT1 in VSMC. Conversely, VSMC-specific SIRT1 overexpression prevented diet-induced arterial stiffness. The antistiffness effect of SIRT1 has been attributable to its anti-inflammatory and antioxidant properties mediated by NF-κB inhibition and downregulation of VCAM-1 and p47phox.

Resveratrol downregulates angiotensin II (AngII) type 1 receptor expression in VSMC through SIRT1 activation. Moreover, resveratrol treatment decreases serum AngII level and the aortic expression of prorenin receptor (PRR) and angiotensin converting enzyme (ACE) and increases serum Ang(1–7) level and the expression of ACE2, AngII type 2 receptor (AT2R), and Mas receptor (MasR). These mechanisms (modulation of the renin–angiotensin system) have been made responsible for the protective effects of resveratrol on aging-induced vascular fibrosis and kidney fibrosis.

4. Effects of Resveratrol on Immune Cells

Although leukocytes do not belong to the resident cells of the vascular wall, they contribute to the pathogenesis of cardiovascular disease. Activated endothelial cells express adhesion molecules on their surface, leading to cell–cell interaction and immune cell infiltration into the vascular wall. Resveratrol modulates the function of immune cells, including CD4+/CD8+ T cells, regulatory T cells, natural killer (NK) cells, polymorphonuclear leukocytes, and monocytes.

Resveratrol prevents the interaction between immune cells and endothelial cells. On the one hand, resveratrol (10–100 µM) inhibits the expression and binding activity of chemokine receptors on leukocytes, e.g., CCR2 on monocytes. On the other hand, resveratrol (0.1–1 µM) also reduces the expression of adhesion molecules on endothelial cells. Reduced macrophage infiltration and ameliorated vascular inflammation by resveratrol have also been demonstrated in vivo.

5. Effects of Resveratrol on PVAT

The perivascular adipose tissue (PVAT) is now considered an important regulator of vascular function by secreting a large number of vasoactive substances, including NO. We have recently seen that the importance of PVAT-eNOS may even exceed that of endothelial eNOS under certain conditions. In the thoracic aorta of diet-induced obese mice, for example, vascular dysfunction can only be observed if PVAT is kept in place. In aortae without PVAT of mice with obesity, vascular function remains normal. This observation has led to the hypothesis that the reduction of NO-dependent vasodilation in obese mice is not due to a dysfunction of eNOS in the endothelium but in the PVAT. Indeed, vascular function of the obese mice can be normalized by pharmacological improvements of PVAT-eNOS function.

Interestingly, resveratrol has been shown to improve PVAT function. The acetylcholine-induced relaxation of aortae from normal rats is inhibited by conditioned media derived from PVAT of rats fed with fructose or HFD. The fructose- and HFD-induced PVAT dysfunction is largely reversed by an oral treatment with resveratrol (20 mg/kg for 8 weeks). Similar PVAT dysfunction can be induced by an in vitro incubation of PVAT with palmitic acid. The palmitic acid-induced PVAT dysfunction is normalized by resveratrol (10 µM), an effect that is prevented by either the AMPK inhibitor compound C or the SIRT1 inhibitor nicotinamide. Because these experiments are performed using PVAT-derived conditioned media, the observed protective effects of resveratrol can be clearly attributed to PVAT.

6. Effects of Resveratrol on Vascular Function and Blood Pressure in Vivo

Antihypertensive effects of resveratrol have been observed in several animal models. These include genetic hypertension (e.g., spontaneously hypertensive rats [SHR]), AngII-induced hypertension, renal models of hypertension, DOCA salt hypertension, programmed hypertension and diet-induced metabolic syndromes. Increased endothelial NO production, reduced vascular oxidative stress, and the resulting improvement of vascular function are likely the major molecular mechanisms underlying the blood pressure-lowering effects of resveratrol (Table 5).

Interestingly, fecal microbiome transplants from resveratrol-treated healthy mice reduce the systolic blood pressure and left ventricular mass of hypertensive mice.

7. Conclusions

Resveratrol increases endothelial NO production, decreases ET-1 synthesis, reduces vascular oxidative stress, and prevents smooth muscle proliferation, vascular remodeling, and arterial stiffness. In addition, resveratrol also inhibits immune cells infiltration into the vascular wall and mitigates vascular inflammation. All these mechanisms contribute to the in vivo effects of resveratrol on vascular function and blood pressure.

References 133

  1. 1.

    Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004;24:2783-2840.

    Not in our library

  2. 2.

    Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006;5:493-506.

    Not in our library10.1038/nrd2060 (opens in a new tab)

  3. 3.

    Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Ann. N. Y. Acad. Sci. 2011;1215:150-160.

    Not in our library10.1111/j.1749-6632.2010.05852.x (opens in a new tab)

  4. 4.
    Resveratrol: French Paradox Revisited · 2012
    No notice
  5. 5.

    Pirola L., Frojdo S. Resveratrol: One molecule, many targets. IUBMB Life. 2008;60:323-332.

    Not in our library10.1002/iub.47 (opens in a new tab)

  6. 6.

    Harikumar K.B., Aggarwal B.B. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020-1035.

    Not in our library10.4161/cc.7.8.5740 (opens in a new tab)

  7. 7.

    Li H., Xia N., Forstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide. 2012;26:102-110.

    Not in our library10.1016/j.niox.2011.12.006 (opens in a new tab)

  8. 8.

    Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., E S.Y., Lamming D.W., et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013;339:1216-1219.

    Not in our library10.1126/science.1231097 (opens in a new tab)

  9. 9.

    Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191-196.

    Not in our library10.1038/nature01960 (opens in a new tab)

  10. 10.
    The Concise Guide to PHARMACOLOGY 2015/16: Enzymes · 2015
    No notice
  11. 11.

    Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421-433.

    Not in our library10.1016/j.cell.2012.01.017 (opens in a new tab)

  12. 12.

    Liu B., Ghosh S., Yang X., Zheng H., Liu X., Wang Z., Jin G., Zheng B., Kennedy B.K., Suh Y., et al. Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab. 2012;16:738-750.

    Not in our library10.1016/j.cmet.2012.11.007 (opens in a new tab)

  13. 13.

    Csiszar A., Labinskyy N., Pinto J.T., Ballabh P., Zhang H., Losonczy G., Pearson K., de Cabo R., Pacher P., Zhang C., et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009;297:H13-H20.

    Not in our library10.1152/ajpheart.00368.2009 (opens in a new tab)

  14. 14.

    Xia N., Strand S., Schlufter F., Siuda D., Reifenberg G., Kleinert H., Forstermann U., Li H. Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide. 2013;32:29-35.

    Not in our library10.1016/j.niox.2013.04.001 (opens in a new tab)

  15. 15.

    Xia N., Daiber A., Forstermann U., Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017;174:1633-1646.

    Not in our library10.1111/bph.13492 (opens in a new tab)

  16. 16.

    Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K., de Cabo R., Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H18-H24.

    Not in our library10.1152/ajpheart.00260.2010 (opens in a new tab)

  17. 17.
    Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation · 2010
    No notice
  18. 18.

    Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA. 2007;104:7217-7222.

    Not in our library10.1073/pnas.0610068104 (opens in a new tab)

  19. 19.

    Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., Lan F., Walsh K., Wierzbicki M., Verbeuren T.J., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008;283:20015-20026.

    Not in our library10.1074/jbc.m802187200 (opens in a new tab)

  20. 20.

    Lan F., Cacicedo J.M., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008;283:27628-27635.

    Not in our library10.1074/jbc.m805711200 (opens in a new tab)

  21. 21.

    Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan F., Ido Y. AMPK and SIRT1: A long-standing partnership? Am. J. Physiol. Endocrinol. Metab. 2010;298:E751-E760.

    Not in our library10.1152/ajpendo.00745.2009 (opens in a new tab)

  22. 22.

    Haigis M.C., Sinclair D.A. Mammalian sirtuins: Biological insights and disease relevance. Annu. Rev. Pathol. 2010;5:253-295.

    Not in our library10.1146/annurev.pathol.4.110807.092250 (opens in a new tab)

  23. 23.

    Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141:3657-3667.

    Not in our library10.1210/endo.141.10.7721 (opens in a new tab)

  24. 24.

    Klinge C.M., Blankenship K.A., Risinger K.E., Bhatnagar S., Noisin E.L., Sumanasekera W.K., Zhao L., Brey D.M., Keynton R.S. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem. 2005;280:7460-7468.

    Not in our library10.1074/jbc.m411565200 (opens in a new tab)

  25. 25.

    Klinge C.M., Wickramasinghe N.S., Ivanova M.M., Dougherty S.M. Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J. 2008;22:2185-2197.

    Not in our library10.1096/fj.07-103366 (opens in a new tab)

  26. 26.

    Yu H.P., Hwang T.L., Hwang T.L., Yen C.H., Lau Y.T. Resveratrol prevents endothelial dysfunction and aortic superoxide production after trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway. Crit. Care Med. 2010;38:1147-1154.

    Not in our library10.1097/ccm.0b013e3181cd124e (opens in a new tab)

  27. 27.

    Nagaoka T., Hein T.W., Yoshida A., Kuo L. Resveratrol, a component of red wine, elicits dilation of isolated porcine retinal arterioles: Role of nitric oxide and potassium channels. Investig. Ophthalmol. Vis. Sci. 2007;48:4232-4239.

    Not in our library10.1167/iovs.07-0094 (opens in a new tab)

  28. 28.

    Gojkovic-Bukarica L., Novakovic A., Kanjuh V., Bumbasirevic M., Lesic A., Heinle H. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J. Pharmacol. Sci. 2008;108:124-130.

    Not in our library10.1254/jphs.08128fp (opens in a new tab)

  29. 29.

    Protic D., Radunovic N., Spremovic-Radenovic S., Zivanovic V., Heinle H., Petrovic A., Gojkovic-Bukarica L. The Role of Potassium Channels in the Vasodilatation Induced by Resveratrol and Naringenin in Isolated Human Umbilical Vein. Drug. Dev. Res. 2015;76:17-23.

    Not in our library10.1002/ddr.21236 (opens in a new tab)

  30. 30.

    Kim T.T., Parajuli N., Sung M.M., Bairwa S.C., Levasseur J., Soltys C.M., Wishart D.S., Madsen K., Schertzer J.D., Dyck J.R.B. Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice. Am. J. Physiol. Endocrinol. Metab. 2018;315:E511-E519.

    Not in our library10.1152/ajpendo.00471.2017 (opens in a new tab)

  31. 31.
    Resveratrol, Metabolic Syndrome, and Gut Microbiota · 2018
    No notice
  32. 32.

    Park I., Lee Y., Kim H.D., Kim K. Effect of Resveratrol, a SIRT1 Activator, on the Interactions of the CLOCK/BMAL1 Complex. Endocrinol. Metab. 2014;29:379-387.

    Not in our library10.3803/enm.2014.29.3.379 (opens in a new tab)

  33. 33.

    Nicholson S.K., Tucker G.A., Brameld J.M. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc. Nutr. Soc. 2008;67:42-47.

    Not in our library10.1017/s0029665108006009 (opens in a new tab)

  34. 34.

    Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 2000;190:244-254.

    Not in our library10.1002/(sici)1096-9896(200002)190:3<244::aid-path575>3.0.co;2-8 (opens in a new tab)

  35. 35.

    Li H., Wallerath T., Forstermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide. 2002;7:132-147.

    Not in our library10.1016/s1089-8603(02)00127-1 (opens in a new tab)

  36. 36.

    Zhao Y., Vanhoutte P.M., Leung S.W. Vascular nitric oxide: Beyond eNOS. J. Pharmacol. Sci. 2015;129:83-94.

    Not in our library10.1016/j.jphs.2015.09.002 (opens in a new tab)

  37. 37.

    Li H., Forstermann U. Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr. Pharm. Des. 2009;15:3133-3145.

    Not in our library10.2174/138161209789058002 (opens in a new tab)

  38. 38.

    Forstermann U., Xia N., Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ. Res. 2017;120:713-735.

    Not in our library10.1161/circresaha.116.309326 (opens in a new tab)

  39. 39.

    Li H., Horke S., Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014;237:208-219.

    Not in our library10.1016/j.atherosclerosis.2014.09.001 (opens in a new tab)

  40. 40.

    Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.

    Not in our library10.1038/377239a0 (opens in a new tab)

  41. 41.

    Kuhlencordt P.J., Gyurko R., Han F., Scherrer-Crosbie M., Aretz T.H., Hajjar R., Picard M.H., Huang P.L. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001;104:448-454.

    Not in our library10.1161/hc2901.091399 (opens in a new tab)

  42. 42.

    Liu V.W., Huang P.L. Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res. 2008;77:19-29.

    Not in our library10.1016/j.cardiores.2007.06.024 (opens in a new tab)

  43. 43.

    Nisoli E., Tonello C., Cardile A., Cozzi V., Bracale R., Tedesco L., Falcone S., Valerio A., Cantoni O., Clementi E., et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314-317.

    Not in our library10.1126/science.1117728 (opens in a new tab)

  44. 44.

    Duplain H., Burcelin R., Sartori C., Cook S., Egli M., Lepori M., Vollenweider P., Pedrazzini T., Nicod P., Thorens B., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-345.

    Not in our library10.1161/01.cir.104.3.342 (opens in a new tab)

  45. 45.

    Sansbury B.E., Cummins T.D., Tang Y., Hellmann J., Holden C.R., Harbeson M.A., Chen Y., Patel R.P., Spite M., Bhatnagar A., et al. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ. Res. 2012;111:1176-1189.

    Not in our library10.1161/circresaha.112.266395 (opens in a new tab)

  46. 46.
    Resveratrol and Endothelial Nitric Oxide · 2014
    No notice
  47. 47.

    Li H., Wallerath T., Munzel T., Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide. 2002;7:149-164.

    Not in our library10.1016/s1089-8603(02)00111-8 (opens in a new tab)

  48. 48.

    Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652-1658.

    Not in our library10.1161/01.cir.0000029925.18593.5c (opens in a new tab)

  49. 49.

    Wallerath T., Poleo D., Li H., Forstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: A mechanism that may contribute to its beneficial cardiovascular effects. J. Am. Coll. Cardiol. 2003;41:471-478.

    Not in our library10.1016/s0735-1097(02)02826-7 (opens in a new tab)

  50. 50.

    Wallerath T., Li H., Godtel-Ambrust U., Schwarz P.M., Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide. 2005;12:97-104.

    Not in our library10.1016/j.niox.2004.12.004 (opens in a new tab)

  51. 51.

    Zhang Q.J., Wang Z., Chen H.Z., Zhou S., Zheng W., Liu G., Wei Y.S., Cai H., Liu D.P., Liang C.C. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res. 2008;80:191-199.

    Not in our library10.1093/cvr/cvn224 (opens in a new tab)

  52. 52.

    Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010;459:793-806.

    Not in our library10.1007/s00424-009-0767-7 (opens in a new tab)

  53. 53.

    Heiss E.H., Dirsch V.M. Regulation of eNOS enzyme activity by posttranslational modification. Curr. Pharm. Des. 2014;20:3503-3513.

    Not in our library10.2174/13816128113196660745 (opens in a new tab)

  54. 54.

    Xu Q., Hao X., Yang Q., Si L. Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem. Biophys. Res. Commun. 2009;388:389-394.

    Not in our library10.1016/j.bbrc.2009.08.021 (opens in a new tab)

  55. 55.

    Carrizzo A., Puca A., Damato A., Marino M., Franco E., Pompeo F., Traficante A., Civitillo F., Santini L., Trimarco V., et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension. 2013;62:359-366.

    Not in our library10.1161/hypertensionaha.111.01009 (opens in a new tab)

  56. 56.

    Mattagajasingh I., Kim C.S., Naqvi A., Yamamori T., Hoffman T.A., Jung S.B., DeRicco J., Kasuno K., Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 2007;104:14855-14860.

    Not in our library10.1073/pnas.0704329104 (opens in a new tab)

  57. 57.

    Arunachalam G., Yao H., Sundar I.K., Caito S., Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem. Biophys. Res. Commun. 2010;393:66-72.

    Not in our library10.1016/j.bbrc.2010.01.080 (opens in a new tab)

  58. 58.

    Maas R., Boger R., Luneburg N. ADMA and the role of the genes: Lessons from genetically modified animals and human gene polymorphisms. Pharmacol. Res. 2009;60:475-480.

    Not in our library10.1016/j.phrs.2009.07.012 (opens in a new tab)

  59. 59.

    Frombaum M., Therond P., Djelidi R., Beaudeux J.L., Bonnefont-Rousselot D., Borderie D. Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high-glucose oxidative stress. Free Radic. Res. 2011;45:293-302.

    Not in our library10.3109/10715762.2010.527337 (opens in a new tab)

  60. 60.

    Feron O., Dessy C., Moniotte S., Desager J.P., Balligand J.L. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J. Clin. Investig. 1999;103:897-905.

    Not in our library10.1172/jci4829 (opens in a new tab)

  61. 61.

    Tian C., Zhang R., Ye X., Zhang C., Jin X., Yamori Y., Hao L., Sun X., Ying C. Resveratrol ameliorates high-glucose-induced hyperpermeability mediated by caveolae via VEGF/KDR pathway. Genes Nutr. 2013;8:231-239.

    Not in our library10.1007/s12263-012-0319-1 (opens in a new tab)

  62. 62.

    Penumathsa S.V., Koneru S., Samuel S.M., Maulik G., Bagchi D., Yet S.F., Menon V.P., Maulik N. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: Role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic. Biol. Med. 2008;45:1027-1034.

    Not in our library10.1016/j.freeradbiomed.2008.07.012 (opens in a new tab)

  63. 63.

    Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik G., Menon V.P., Bagchi D., Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell. Mol. Med. 2008;12:2350-2361.

    Not in our library10.1111/j.1582-4934.2008.00251.x (opens in a new tab)

  64. 64.

    Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation. 2006;113:1708-1714.

    Not in our library10.1161/circulationaha.105.602532 (opens in a new tab)

  65. 65.

    Li H., Forstermann U. Pharmacological Prevention of eNOS Uncoupling. Curr. Pharm. Des. 2014;20:3595-3606.

    Not in our library10.2174/13816128113196660749 (opens in a new tab)

  66. 66.

    Li H., Forstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr. Opin. Pharmacol. 2013;13:161-167.

    Not in our library10.1016/j.coph.2013.01.006 (opens in a new tab)

  67. 67.

    Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai T., Harrison D.G. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.

    Not in our library10.1161/01.cir.103.9.1282 (opens in a new tab)

  68. 68.

    Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Investig. 2003;111:1201-1209.

    Not in our library10.1172/jci200314172 (opens in a new tab)

  69. 69.

    Alp N.J., McAteer M.A., Khoo J., Choudhury R.P., Channon K.M. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004;24:445-450.

    Not in our library10.1161/01.atv.0000115637.48689.77 (opens in a new tab)

  70. 70.

    Zou M.H., Shi C., Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Investig. 2002;109:817-826.

    Not in our library10.1172/jci0214442 (opens in a new tab)

  71. 71.

    Xia N., Daiber A., Habermeier A., Closs E.I., Thum T., Spanier G., Lu Q., Oelze M., Torzewski M., Lackner K.J., et al. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J. Pharmacol. Exp. Ther. 2010;335:149-154.

    Not in our library10.1124/jpet.110.168724 (opens in a new tab)

  72. 72.

    Liu J.C., Chen J.J., Chan P., Cheng C.F., Cheng T.H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension. 2003;42:1198-1205.

    Not in our library10.1161/01.hyp.0000103162.76220.51 (opens in a new tab)

  73. 73.

    Spanier G., Xu H., Xia N., Tobias S., Deng S., Wojnowski L., Forstermann U., Li H. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J. Physiol. Pharmacol. 2009;60(Suppl. 4):111-116.

    Not in our library

  74. 74.

    Ungvari Z., Orosz Z., Rivera A., Labinskyy N., Xiangmin Z., Olson S., Podlutsky A., Csiszar A. Resveratrol increases vascular oxidative stress resistance. Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2417-H2424.

    Not in our library10.1152/ajpheart.01258.2006 (opens in a new tab)

  75. 75.

    Ungvari Z., Labinskyy N., Mukhopadhyay P., Pinto J.T., Bagi Z., Ballabh P., Zhang C., Pacher P., Csiszar A. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009;297:H1876-H1881.

    Not in our library10.1152/ajpheart.00375.2009 (opens in a new tab)

  76. 76.

    Xia N., Forstermann U., Li H. Resveratrol as a gene regulator in the vasculature. Curr. Pharm. Biotechnol. 2014;15:401-408.

    Not in our library10.2174/1389201015666140711114450 (opens in a new tab)

  77. 77.

    Corder R., Douthwaite J.A., Lees D.M., Khan N.Q., Viseu Dos Santos A.C., Wood E.G., Carrier M.J. Endothelin-1 synthesis reduced by red wine. Nature. 2001;414:863-864.

    Not in our library10.1038/414863a (opens in a new tab)

  78. 78.

    Zou J.G., Wang Z.R., Huang Y.Z., Cao K.J., Wu J.M. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med. 2003;11:317-320.

    Not in our library10.3892/ijmm.11.3.317 (opens in a new tab)

  79. 79.

    Nicholson S.K., Tucker G.A., Brameld J.M. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br. J. Nutr. 2010;103:1398-1403.

    Not in our library10.1017/s0007114509993485 (opens in a new tab)

  80. 80.

    Coppa T., Lazze M.C., Cazzalini O., Perucca P., Pizzala R., Bianchi L., Stivala L.A., Forti L., Maccario C., Vannini V., et al. Structure-activity relationship of resveratrol and its analogue, 4,4’-dihydroxy-trans-stilbene, toward the endothelin axis in human endothelial cells. J. Med. Food. 2011;14:1173-1180.

    Not in our library10.1089/jmf.2010.0272 (opens in a new tab)

  81. 81.

    Ruef J., Moser M., Kubler W., Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc. Pathol. 2001;10:311-315.

    Not in our library10.1016/s1054-8807(01)00095-3 (opens in a new tab)

  82. 82.

    Chao H.H., Juan S.H., Liu J.C., Yang H.Y., Yang E., Cheng T.H., Shyu K.G. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur. J. Pharmacol. 2005;515:1-9.

    Not in our library10.1016/j.ejphar.2005.03.035 (opens in a new tab)

  83. 83.

    Juan S.H., Cheng T.H., Lin H.C., Chu Y.L., Lee W.S. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem. Pharmacol. 2005;69:41-48.

    Not in our library10.1016/j.bcp.2004.09.015 (opens in a new tab)

  84. 84.

    Kim J.W., Lim S.C., Lee M.Y., Lee J.W., Oh W.K., Kim S.K., Kang K.W. Inhibition of neointimal formation by trans-resveratrol: Role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Mol. Nutr. Food Res. 2010;54:1497-1505.

    Not in our library10.1002/mnfr.201000016 (opens in a new tab)

  85. 85.

    Li Y., Cao Z., Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol. Res. 2006;53:6-15.

    Not in our library10.1016/j.phrs.2005.08.002 (opens in a new tab)

  86. 86.

    Thompson A.M., Martin K.A., Rzucidlo E.M. Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK. PLoS ONE. 2014;9:e85495.

    Not in our library10.1371/journal.pone.0085495 (opens in a new tab)

  87. 87.

    Wang D., Uhrin P., Mocan A., Waltenberger B., Breuss J.M., Tewari D., Mihaly-Bison J., Huminiecki L., Starzynski R.R., Tzvetkov N.T., et al. Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: Molecular targets and pathways. Biotechnol. Adv. 2018;36:1586-1607.

    Not in our library10.1016/j.biotechadv.2018.04.006 (opens in a new tab)

  88. 88.

    Ong E.T., Hwang T.L., Huang Y.L., Lin C.F., Wu W.B. Vitisin B, a resveratrol tetramer, inhibits migration through inhibition of PDGF signaling and enhancement of cell adhesiveness in cultured vascular smooth muscle cells. Toxicol. Appl. Pharmacol. 2011;256:198-208.

    Not in our library10.1016/j.taap.2011.08.013 (opens in a new tab)

  89. 89.

    Park E.S., Lim Y., Hong J.T., Yoo H.S., Lee C.K., Pyo M.Y., Yun Y.P. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul. Pharmacol. 2010;53:61-67.

    Not in our library10.1016/j.vph.2010.04.001 (opens in a new tab)

  90. 90.

    Khandelwal A.R., Hebert V.Y., Kleinedler J.J., Rogers L.K., Ullevig S.L., Asmis R., Shi R., Dugas T.R. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. J. Nutr. 2012;142:1487-1494.

    Not in our library10.3945/jn.112.162628 (opens in a new tab)

  91. 91.

    Orozco-Sevilla V., Naftalovich R., Hoffmann T., London D., Czernizer E., Yang C., Dardik A., Dardik H. Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery. J. Vasc. Surg. 2013;58:1360-1365.

    Not in our library10.1016/j.jvs.2012.11.090 (opens in a new tab)

  92. 92.

    Kleinedler J.J., Foley J.D., Orchard E.A., Dugas T.R. Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. J. Control. Release. 2012;159:27-33.

    Not in our library10.1016/j.jconrel.2012.01.008 (opens in a new tab)

  93. 93.

    Zhu Y., Takayama T., Wang B., Kent A., Zhang M., Binder B.Y., Urabe G., Shi Y., DiRenzo D., Goel S.A., et al. Restenosis Inhibition and Re-differentiation of TGFbeta/Smad3-activated Smooth Muscle Cells by Resveratrol. Sci. Rep. 2017;7:41916.

    Not in our library10.1038/srep41916 (opens in a new tab)

  94. 94.

    Zou J., Huang Y., Chen Q., Wang N., Cao K., Hsieh T.C., Wu J.M. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int. J. Oncol. 1999;15:647-651.

    Not in our library10.3892/ijo.15.4.647 (opens in a new tab)

  95. 95.

    Mizutani K., Ikeda K., Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem. Biophys. Res. Commun. 2000;274:61-67.

    Not in our library10.1006/bbrc.2000.3097 (opens in a new tab)

  96. 96.

    Haider U.G., Sorescu D., Griendling K.K., Vollmar A.M., Dirsch V.M. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol. Pharmacol. 2002;62:772-777.

    Not in our library10.1124/mol.62.4.772 (opens in a new tab)

  97. 97.

    Mnjoyan Z.H., Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: A role of p53-p21(WAF1/CIP1) pathway. Biochem. Biophys. Res. Commun. 2003;311:546-552.

    Not in our library10.1016/j.bbrc.2003.10.023 (opens in a new tab)

  98. 98.

    Haider U.G., Sorescu D., Griendling K.K., Vollmar A.M., Dirsch V.M. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol. Pharmacol. 2003;63:925-932.

    Not in our library10.1124/mol.63.4.925 (opens in a new tab)

  99. 99.

    Poussier B., Cordova A.C., Becquemin J.P., Sumpio B.E. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J. Vasc. Surg. 2005;42:1190-1197.

    Not in our library10.1016/j.jvs.2005.08.014 (opens in a new tab)

  100. 100.

    Lee B., Moon S.K. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J. Nutr. 2005;135:2767-2773.

    Not in our library10.1093/jn/135.12.2767 (opens in a new tab)

  101. 101.

    Wang Z., Chen Y., Labinskyy N., Hsieh T.C., Ungvari Z., Wu J.M. Regulation of proliferation and gene expression in cultured human aortic smooth muscle cells by resveratrol and standardized grape extracts. Biochem. Biophys. Res. Commun. 2006;346:367-376.

    Not in our library10.1016/j.bbrc.2006.05.156 (opens in a new tab)

  102. 102.

    Brito P.M., Devillard R., Negre-Salvayre A., Almeida L.M., Dinis T.C., Salvayre R., Auge N. Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis. 2009;205:126-134.

    Not in our library10.1016/j.atherosclerosis.2008.11.011 (opens in a new tab)

  103. 103.

    Choi K.H., Kim J.E., Song N.R., Son J.E., Hwang M.K., Byun S., Kim J.H., Lee K.W., Lee H.J. Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc. Res. 2010;85:836-844.

    Not in our library10.1093/cvr/cvp359 (opens in a new tab)

  104. 104.

    Fry J.L., Al Sayah L., Weisbrod R.M., Van Roy I., Weng X., Cohen R.A., Bachschmid M.M., Seta F. Vascular Smooth Muscle Sirtuin-1 Protects Against Diet-Induced Aortic Stiffness. Hypertension. 2016;68:775-784.

    Not in our library10.1161/hypertensionaha.116.07622 (opens in a new tab)

  105. 105.

    Miyazaki R., Ichiki T., Hashimoto T., Inanaga K., Imayama I., Sadoshima J., Sunagawa K. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2008;28:1263-1269.

    Not in our library10.1161/atvbaha.108.166991 (opens in a new tab)

  106. 106.

    Jang I.A., Kim E.N., Lim J.H., Kim M.Y., Ban T.H., Yoon H.E., Park C.W., Chang Y.S., Choi B.S. Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney. Nutrients. 2018;10:1741.

    Not in our library10.3390/nu10111741 (opens in a new tab)

  107. 107.

    Kim E.N., Kim M.Y., Lim J.H., Kim Y., Shin S.J., Park C.W., Kim Y.S., Chang Y.S., Yoon H.E., Choi B.S. The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system. Atherosclerosis. 2018;270:123-131.

    Not in our library10.1016/j.atherosclerosis.2018.01.043 (opens in a new tab)

  108. 108.

    Gresele P., Cerletti C., Guglielmini G., Pignatelli P., de Gaetano G., Violi F. Effects of resveratrol and other wine polyphenols on vascular function: An update. J. Nutr. Biochem. 2011;22:201-211.

    Not in our library10.1016/j.jnutbio.2010.07.004 (opens in a new tab)

  109. 109.

    Rotondo S., Rajtar G., Manarini S., Celardo A., Rotillo D., de Gaetano G., Evangelista V., Cerletti C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br. J. Pharmacol. 1998;123:1691-1699.

    Not in our library10.1038/sj.bjp.0701784 (opens in a new tab)

  110. 110.

    Cullen J.P., Morrow D., Jin Y., von Offenberg Sweeney N., Sitzmann J.V., Cahill P.A., Redmond E.M. Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis. 2007;195:e125-e133.

    Not in our library10.1016/j.atherosclerosis.2007.03.039 (opens in a new tab)

  111. 111.

    Li Q., Huyan T., Ye L.J., Li J., Shi J.L., Huang Q.S. Concentration-dependent biphasic effects of resveratrol on human natural killer cells in vitro. J. Agric. Food Chem. 2014;62:10928-10935.

    Not in our library10.1021/jf502950u (opens in a new tab)

  112. 112.

    Pendurthi U.R., Williams J.T., Rao L.V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler. Thromb. Vasc. Biol. 1999;19:419-426.

    Not in our library10.1161/01.atv.19.2.419 (opens in a new tab)

  113. 113.

    Ferrero M.E., Bertelli A.E., Fulgenzi A., Pellegatta F., Corsi M.M., Bonfrate M., Ferrara F., De Caterina R., Giovannini L., Bertelli A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr. 1998;68:1208-1214.

    Not in our library10.1093/ajcn/68.6.1208 (opens in a new tab)

  114. 114.

    Guo R., Liu B., Wang K., Zhou S., Li W., Xu Y. Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-kappaB pathway. Diab. Vasc. Dis. Res. 2014;11:92-102.

    Not in our library10.1177/1479164113520332 (opens in a new tab)

  115. 115.

    Xia N., Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br. J. Pharmacol. 2017;174:3425-3442.

    Not in our library10.1111/bph.13650 (opens in a new tab)

  116. 116.

    Xia N., Forstermann U., Li H. Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue. Ann. N. Y. Acad. Sci. 2017;1403:132-141.

    Not in our library10.1111/nyas.13397 (opens in a new tab)

  117. 117.

    Xia N., Horke S., Habermeier A., Closs E.I., Reifenberg G., Gericke A., Mikhed Y., Munzel T., Daiber A., Forstermann U., et al. Uncoupling of Endothelial Nitric Oxide Synthase in Perivascular Adipose Tissue of Diet-Induced Obese Mice. Arterioscler. Thromb. Vasc. Biol. 2016;36:78-85.

    Not in our library10.1161/atvbaha.115.306263 (opens in a new tab)

  118. 118.

    Xia N., Weisenburger S., Koch E., Burkart M., Reifenberg G., Forstermann U., Li H. Restoration of perivascular adipose tissue function in diet-induced obese mice without changing bodyweight. Br. J. Pharmacol. 2017;174:3443-3453.

    Not in our library10.1111/bph.13703 (opens in a new tab)

  119. 119.

    Sun Y., Li J., Xiao N., Wang M., Kou J., Qi L., Huang F., Liu B., Liu K. Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol. Res. 2014;89:19-28.

    Not in our library10.1016/j.phrs.2014.07.006 (opens in a new tab)

  120. 120.

    Chen Y., Xu X., Zhang Y., Liu K., Huang F., Liu B., Kou J. Diosgenin regulates adipokine expression in perivascular adipose tissue and ameliorates endothelial dysfunction via regulation of AMPK. J. Steroid Biochem. Mol. Biol. 2016;155 Pt A:155-165.

    Not in our library10.1016/j.jsbmb.2015.07.005 (opens in a new tab)

  121. 121.

    Zordoky B.N., Robertson I.M., Dyck J.R. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta. 2015;1852:1155-1177.

    Not in our library10.1016/j.bbadis.2014.10.016 (opens in a new tab)

  122. 122.

    Park E.J., Pezzuto J.M. The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta. 2015;1852:1071-1113.

    Not in our library10.1016/j.bbadis.2015.01.014 (opens in a new tab)

  123. 123.

    Bhatt S.R., Lokhandwala M.F., Banday A.A. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur. J. Pharmacol. 2011;667:258-264.

    Not in our library10.1016/j.ejphar.2011.05.026 (opens in a new tab)

  124. 124.

    Dolinsky V.W., Chakrabarti S., Pereira T.J., Oka T., Levasseur J., Beker D., Zordoky B.N., Morton J.S., Nagendran J., Lopaschuk G.D., et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta. 2013;1832:1723-1733.

    Not in our library10.1016/j.bbadis.2013.05.018 (opens in a new tab)

  125. 125.

    Liu Z., Song Y., Zhang X., Liu Z., Zhang W., Mao W., Wang W., Cui W., Zhang X., Jia X., et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin. Exp. Pharmacol. Physiol. 2005;32:1049-1054.

    Not in our library10.1111/j.1440-1681.2005.04299.x (opens in a new tab)

  126. 126.

    Toklu H.Z., Sehirli O., Ersahin M., Suleymanoglu S., Yiginer O., Emekli-Alturfan E., Yarat A., Yegen B.C., Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J. Pharm. Pharmacol. 2010;62:1784-1793.

    Not in our library10.1111/j.2042-7158.2010.01197.x (opens in a new tab)

  127. 127.

    Chan V., Fenning A., Iyer A., Hoey A., Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr. Pharm. Biotechnol. 2011;12:429-436.

    Not in our library10.2174/138920111794480552 (opens in a new tab)

  128. 128.

    Franco J.G., Lisboa P.C., Lima N.S., Amaral T.A., Peixoto-Silva N., Resende A.C., Oliveira E., Passos M.C., Moura E.G. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J. Nutr. Biochem. 2013;24:960-966.

    Not in our library10.1016/j.jnutbio.2012.06.019 (opens in a new tab)

  129. 129.

    Aubin M.C., Lajoie C., Clement R., Gosselin H., Calderone A., Perrault L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: Therapeutic potential of resveratrol. J. Pharmacol. Exp. Ther. 2008;325:961-968.

    Not in our library10.1124/jpet.107.135061 (opens in a new tab)

  130. 130.

    Miatello R., Vazquez M., Renna N., Cruzado M., Zumino A.P., Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens. 2005;18:864-870.

    Not in our library10.1016/j.amjhyper.2004.12.012 (opens in a new tab)

  131. 131.

    Akar F., Uludag O., Aydin A., Aytekin Y.A., Elbeg S., Tuzcu M., Sahin K. High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: Protective effect of resveratrol. Food Chem. Toxicol. 2012;50:2135-2141.

    Not in our library10.1016/j.fct.2012.03.061 (opens in a new tab)

  132. 132.

    Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009;77:1053-1063.

    Not in our library10.1016/j.bcp.2008.11.027 (opens in a new tab)

  133. 133.

    Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 2000;46:78-83.

    Not in our library10.3177/jnsv.46.78 (opens in a new tab)

Cited by papers we hold 5

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.